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Edited by Robert BaroukiAbstract Many types of cancer cells constitutively express ma-
jor molecular chaperones at high levels. Recent ﬁndings demon-
strate that speciﬁc depletion of individual chaperones, including
various members of the Hsp70 family, small heat shock proteins,
or VCP/p97, leads to activation of p53 pathway and subse-
quently triggers cellular senescence. Here, we discuss a possibil-
ity that in cancer cells high levels of chaperones serve to keep the
p53 signaling under control, thus allowing cancer cells to evade
the default senescence and form tumors.
 2007 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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p21; p53; CancerIt is generally accepted that apoptosis plays the major role in
control of cancer development. In fact, cells encounter multiple
apoptotic stimuli during cancer progression, including activa-
tion of pro-apoptotic myc oncogene [1–3], anoikis, i.e. sub-
strate detachment-induced apoptosis upon invasion and
metastases [4], apoptotic stimuli of tumor milieu, like TNF,
FAS, hypoxia, nutrient deprivation, etc. [5,6]. Accordingly, it
was suggested that the well-documented anti-apoptotic poten-
tial of the heat shock proteins may play a critical role in sup-
pression of apoptosis in cancer cells [7,8]. In line with this
suggestion, recent research from many labs dissected multiple
eﬀects of the major heat shock proteins, Hsp72 and Hsp27,
on various components of multiple apoptotic pathways [9–
11], including Bax, JNK, FAS receptor, Smad, lysosome
stability, and others. However, direct involvement of Hsps in
suppression of cancer-related apoptosis has not been clearly
conﬁrmed. More recently, the attention of the cancer commu-
nity has shifted towards a novel role of cell senescence in con-
trol of cancer development, and with this shift our view on the
role of Hsps in cancer has also evolved towards appreciation of
the major role of Hsps in regulation of the senescence pro-
gram.
Cellular senescence was originally described as a limit to a
number of divisions that a normal cell can undergo. For exam-
ple, normal ﬁbroblasts can divide about 60 times in culture be-
fore acquiring a speciﬁc ‘‘ﬂat’’ morphology and becoming
permanently growth arrested [12,13]. Epithelial, endothelial
or hematopoetic cells also have a limit on the number of divi-
sions, which is usually below twenty [14–19]. Originally it was*Corresponding author. Fax: +1 617 638 5339.
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the telomers shortening, but at present it became clear that
senescence could be triggered by various types of DNA dam-
age that results in accumulation of cell cycle inhibitors p16
and p21 [20–24]. Senescence is a very complex program with
multiple end points that include not only growth arrest, but
also enlargement of cells, extensive vacuolization, repression
and de-repression of certain sets of genes, secretion of various
signaling molecules, inhibition of the heat shock response, and
other manifestations.
The senescence program seems to represent one of the major
breaks on cancer emergence. Indeed, limiting cell divisions
seems to be a perfect way of preventing tumor growth [25]. An-
other alternative to achieve the same goal is through activation
of apoptosis. Mammalian cells appear to utilize both programs
to counteract action of the major oncogenes. In fact, as coun-
terintuitive, as it sounds overexpression of major oncogenes
could either activate apoptosis, as seen with myc, or trigger
senescence as seen with Ras, Her-2, PTEN, Raf, and others
oncogenes of the Ras pathway [26–32].
The discovery that cancer cells could become senescent was
quite unexpected since tumor cells by deﬁnition divide indeﬁ-
nitely. Nevertheless, being unrestrained by the replicative
senescence, many cancer cells still could undergo senescence
(so-called premature senescence) in response to activation of
oncogenes (Fig. 1), e.g. Ras or Her-2, or to various DNA-dam-
aging drugs, like doxorubicin [33,34]. In fact, the major mech-
anism of action of many anti-cancer drugs seems to be
activation of the premature senescence program [35,36]. These
ﬁndings demonstrate that the senescence program remains
functional even after cancer transformation. Premature senes-
cence in cancer cells depends upon activation of the cell cycle
inhibitor p21, while p16 seems to be involved only in senes-
cence of normal cells.
In general oncogenes of Ras pathway activate the senescence
program via several mechanisms that involve activation of
p53, the transcriptional activator of p21. For example, these
oncogenes can activate the DNA damage response kinases
ATM and ATR because of excessive activation of DNA repli-
cation forks, and these kinases phosphorylate and stabilize p53
[37]. Another mechanism involves induction of p19ARF that
inhibits the p53 ubiquitin ligase Hdm2, also leading to stabil-
ization of p53 [38]. In turn stabilization of p53 leads to its
accumulation and activation. Since cancer cells have active
oncogenes that can trigger cell senescence, in order to prolifer-
ate they have to acquire mechanisms that completely or
partially suppress p21. Indeed, it is well known that muta-
tions in p21 or mutations that result in disabling of p21blished by Elsevier B.V. All rights reserved.
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Fig. 1. Hsps can suppress p53 and allow proliferation of cells with activated oncogenes. Oncogenes of Ras pathway activate two parallel pathways,
including the proliferation response and the growth inhibitory p53 pathway. Normally p53 induces p21 and causes growth arrest and senescence, thus
preventing cell proliferation. However, proliferating cells acquire mutations in the p53 pathway. Alternatively, high levels of Hsps inhibit p53 and
allow cells to proliferate.
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man cancers. However, in many cancer types the p53 pathway
remains functional, and therefore alternative mechanisms of
suppression of p21 must operate in these tumors.
How cancer cells with activated oncogenes and intact p53
pathway escape senescence? Cancer cells constitutively overex-
press several major chaperones [39]. It appears that these chap-
erones play an important role in suppressing the senescent
program, thus allowing cancer cells to proliferate. A critical
observation on the role of chaperones in suppression of cellu-
lar senescence was the ﬁnding that a speciﬁc downregulation of
Hsp70-2, a member of Hsp70 family, leads to rapid senescence
of various cancer cell lines [40,41]. Hsp70-2 was originally de-
scribed as a testis-speciﬁc chaperone, but more recently it be-
came clear that it is widely expressed in a variety of cancer
cell types [40,41]. Depletion of this protein using siRNA ap-
proach caused permanent G1 arrest, cell enlargement and ﬂat-
tening typical for senescent cells. These alterations were
associated with up-regulation of p53. Gene array analysis
showed that expression of a large number of genes was signif-
icantly altered (up- or downregulated) upon Hsp70-2 deple-
tion. The pattern of the gene expression alterations had a lot
of similarities to that found in senescence caused by doxorubi-
cin [40,42,43]. One of the genes upregulated at both conditions
was MIC-1, a cytokine of TGFb family, which appeared to be
critical for senescence. In fact, expression of siRNA against
MIC-1 prevented development of ﬂat morphology and other
hallmarks of senescence after depletion of Hsp70-2. Overpro-
duction of MIC-1 is controlled by p53. Therefore the primary
eﬀect of Hsp70-2 depletion seems to involve p53 activation,
which in turn triggers the senescence program. It is likely that
this process involves induction of p21, because it is a direct p53
transcriptional target. On the other hand, MIC-1 appears to
serve as an additional critical p53-dependent co-stimulator of
cell senescence. It is likely that MIC-1 is secreted from cells
and further promotes the senescence program, thus providing
both autocrine and, possibly, paracrine stimulation. Thus,
Hsp70-2 seems to play a role in keeping p53 pathway sup-
pressed, and Hsp70-2 depletion leads to the abrogation of this
control and reactivation of the default senescence program.A distinct member of the Hsp70 family, the major inducible
heat shock protein Hsp72 plays a similar function in cancer
cells, though the ways of controlling the p53 pathway by
Hsp70-2 and Hsp72 appear to be diﬀerent (see below). Deple-
tion of Hsp72 led to a strong activation of p53, induction of
p21, cell cycle arrest at both G1 and G2 phases, appearance
of acidic b-gal activity and other hallmarks of senescence
[44]. Previously, Hsp72 was shown to bind p53 [45,46] and re-
tain it in cytoplasm, implying that depletion of Hsp72 would
release p53 and allow its nuclear translocation and activation
of the transcription targets. In addition, p53 was stabilized
upon depletion of Hsp72, due to reduction of activity of the
p53 ubiquitin ligase Hdm2. Deﬁning the primary eﬀect of
Hsp72 depletion on p53 pathway is rather tricky since p53
and Hdm2 represent a negative feedback loop, where p53 in-
duces Hdm2, while Hdm2 facilitate degradation of p53. How-
ever, it was shown that suppression of Hdm2 upon Hsp72
depletion is the primary event, since under these conditions
inhibition of Hdm2 was seen even in p53 knockout cells [44].
Interestingly, though p53 and p21 clearly contributed to
development of senescence in Hsp72-depleted cells, other path-
ways also appear to be involved since a signiﬁcant senescence
was seen after Hsp72 depletion in p53 knockout colon carci-
noma HCT-116 cells. The p53-independent senescence path-
way under these conditions was associated with the
reduction of expression and increase in the inhibitory phos-
phorylation of the cdc2 kinase [44]. In line with this ﬁnding,
partial depletion of cdc2 also caused senescence in p53 knock-
out cells.
There are reports that yet another member of the Hsp70
family, i.e. mitochondrial chaperone Grp75 also could activate
senescence pathway through the control of p53. Being the ma-
jor mitochondrial chaperone, Grp75 shows a pan-cytosolic
localization in normal cells. Upon immortalization, however,
it changes its localization and moves into the perinuclear zone
[47,48]. Association of this protein with cell immortalization is
reﬂected in its alternative name, mot-2 (mortalin). Interest-
ingly, overexpression of mot-2 protein in C. elegans signiﬁ-
cantly extended the worm’s life span [49]. Importantly,
overexpression of mot-2 in normal human lung ﬁbroblasts
M. Sherman et al. / FEBS Letters 581 (2007) 3711–3715 3713led to a temporal escape of ﬁbroblasts from the replicative
senescence, allowing extra 12–18 doublings [50]. Eﬀects of
mot-2 on temporal suppression of senescence were associated
with inhibition of p53. Mot-2 directly interacts with p53 and
suppresses its activity by sequestering p53 in cytosol [51–53].
Accordingly, disruption of mot-2 – binding to p53 by speciﬁc
peptides leads to p53 translocation to nucleus and concurrent
activation [54]. Therefore, several major Hsp70 family mem-
bers appear to be involved in the control of p53.
Members of the Hsp70 family are not unique in their ability
to interfere with senescence, as depletion of Hsp27 in trans-
formed cells, similarly led to activation of the senescence pro-
gram. In fact, upon siRNA-mediated depletion of Hsp27
human colon tumor cells HCT-116 acquired all major hall-
marks of senescence associated with activation of p53 and
induction of p21 [55]. Similar eﬀects were seen upon depletion
in HeLa cells of a distinct chaperone vcp/p97 that controls
delivery of ubiquitinated substrates to proteasome. Vcp/p97
downregulation led to activation of p53 and subsequent p21
induction and cell cycle arrest accompanied by cell ﬂattening,
vacuolization, and enlargement [56].
As discussed previously, some chaperons could directly inter-
act with p53 and suppress its activity. In addition, the fact that
depletion of diﬀerent chaperones results in activation of p53
and leads to senescence suggests that these eﬀects could be med-
iated through the chaperones’ general involvement in protein
folding and degradation. In fact, there is a possibility that
depletion of individual chaperones may reduce a refolding/deg-
radation capacity of cells, thus causing a build-up of abnormal
polypeptides, proteotoxicity and subsequent activation of p53.
In line with this suggestion, certain protein damaging stresses
that cause a build-up of abnormal polypeptides, like heat shock
or oxidative stress, lead to activation of p53 [57–59]. However,
surprisingly, targeted depletion of individual chaperones Hsp72
or Hsp27 in HCT-116 cells did not result in accumulation of
abnormal protein species. Accordingly, no accumulation of
oxidized or ubiquitinated proteins were detected [55]. Ubiqui-
tin–proteasome degradation and refolding of model substrates
were normal, indicating that UPS and the chaperone machinery
were not overwhelmed. Moreover, there was no activation of
the heat shock response, suggesting the lack of the proteotoxic
stress [55]. Furthermore, depletion of either Hsp72 or Hsp27
had only minor eﬀects on heat shock sensitivity of these cells,
as judged by activation of apoptosis. Therefore, eﬀects of deple-
tion of individual chaperones on the p53 pathway appear to
control this pathway by speciﬁc mechanisms, rather than
through evoking general proteotoxic stress. Findings that dis-
tinct chaperones are involved in control of the p53 and possibly
other senescence pathways may help to explain why chaperones
are often overexpressed in a variety of cancers. In fact, high
expression of Hsp72 and Hsp27 often correlates with the grade
of tumors, drug resistance and overall poor prognosis. Simi-
larly, Hsp70-2, mot-2 and vcp/p97 were reported to be highly
expressed in various tumors, and with some tumors they could
be used as prognostic factors [39]. Therefore cancer cells in con-
trast to normal cells selectively overproduce these chaperones
individually or together. The overproduction of chaperones
in tumors could be achieved through various mechanisms,
including overexpression of the major heat shock transcription
factor Hsf1 [60,61], phosphorylation of Hsf1 by Akt kinase
activated by certain oncogenes [62], expression of a splicing iso-
form of p63 [63] and probably other mechanisms.What could be the speciﬁc physiological signiﬁcance of in-
creased chaperone expression in cancers? As mentioned above,
activation of certain oncogenes (e.g. Ras, Her-2 or PTEN
mutation) in normal cells stimulate p53 and forces cells to se-
nesce, which serves as an important defense mechanism against
cancer transformation. Depletion of various chaperones trig-
gers senescence suggesting that chaperones serve as endoge-
nous suppressors of a latent senescence program. In other
words, in many cancers various chaperones keep p53 under
control, thus allowing cancer transformation to occur
(Fig. 1). It is possible that tumors accumulate chaperones as
a means to avoid the oncogene-induced senescence. This mech-
anism of evading activation of the senescence program in tu-
mors could be an alternative to acquiring mutations in p53
pathway, which takes place in a large fraction of tumors. All
together these data imply that heat shock proteins could serve
as new important targets for anticancer therapies.References
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